PremiumRatingsAN2 Therapeutics, Inc.: Hold Rating Amid Mixed Clinical Results and Stable Financial Outlook AN2 Therapeutics, Inc.: Promising Future with Strong Financial Health and Strategic Advancements AN2 Therapeutics reports Q4 EPS (25c) vs (57c) last year PremiumThe FlyJMP Securities healthcare analysts hold an analyst/industry conference call AN2 Therapeutics downgraded to Hold from Buy at TD Cowen AN2 Therapeutics reports Q3 EPS (43c), consensus (38c) PremiumThe FlyMorning Movers: Iteris skyrockets following take-private agreement AN2 Therapeutics downgraded to Underperform from In Line at Evercore ISI AN2 Therapeutics to terminate Phase 2, Phase 3 parts of EBO-301 trial 
